351. The effect of gender and ABCB1 gene polymorphism on the pharmacokinetics of azithromycin in healthy male and female Pakistani subjects.
- Author
-
Nazir S, Adnan K, Gul R, Ali G, Saleha S, and Khan A
- Subjects
- Adult, Female, Humans, Male, Pakistan, Young Adult, ATP Binding Cassette Transporter, Subfamily B, Member 1 genetics, Azithromycin pharmacokinetics, Healthy Volunteers, Polymorphism, Single Nucleotide, Sex Characteristics
- Abstract
In the current study, the possible outcome of gender difference and genotypic polymorphism of the ABCB1 gene encoding P-glycoprotein on the pharmacokinetics of azithromycin has been evaluated. An open-label, comparative pharmacokinetic study was done in healthy Pakistani volunteers (females ( n = 8) and males ( n = 8)). They were administered a single 500 mg oral dose of azithromycin. Blood samples (≈5 mL) were collected in heparinized tubes and the HPLC/MS/MS method was used to determine azithromycin plasma levels. ABCB1 polymorphism (single nucleotide polymorphisms) at C3435T, G26SST was performed using the RFLP-PCR method. The Student t test was applied to compare pharmacokinetic parameters of azithromycin between male and female human subjects (at 95% CI) using GraphPad Prism-8. A significant difference was observed in pharmacokinetic parameters between males and females, as C
max in males (230 ± 80.2 ng/mL) was significantly higher than in females (224.9 ± 75.5 ng/mL), while [Formula: see text] was also significantly higher ( p < 0.05) in males (2102 ± 200.3 ng·h-1 ·mL-1 ) compared to females (1825.7 ± 225.4 ng·h-1 ·mL-1 ). There was a significant variation in Cmax and AUC in three ABCB1 genotyping groups as well. Gender difference and ABCB1 gene polymorphisms have a significant impact on the pharmacokinetics of azithromycin, as they contribute to interindividual variability in therapeutic response.- Published
- 2020
- Full Text
- View/download PDF